paclitaxel has been researched along with Bone Cancer in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (10.62) | 18.2507 |
| 2000's | 110 (48.67) | 29.6817 |
| 2010's | 78 (34.51) | 24.3611 |
| 2020's | 14 (6.19) | 2.80 |
| Authors | Studies |
|---|---|
| Aschero, R; Burgueño, V; Carcaboso, AM; Castillo-Ecija, H; de Álava, E; Gómez-Caballero, A; Gomez-Gonzalez, S; Ibarra, M; Mora, J; Muñoz-Aznar, O; Pascual-Pasto, G; Resa-Pares, C; Schaiquevich, P; Sosnik, A; Suñol, M; Tirado, OM; Unceta, N; Vila-Ubach, M | 1 |
| Cai, JX; Li, YJ; Liu, JH; Qiu, XH; Wu, JY; Xiang, DX; Xu, P; Xu, WJ | 1 |
| Ahangar, NK; Alizadeh, N; Baghbanzadeh, A; Baradaran, B; Dolatkhah, K; Khalaj-Kondori, M; Mokhtarzadeh, A; Shadbad, MA | 1 |
| Aschero, R; Balaguer-Lluna, L; Baulenas-Farres, M; Burgueño, V; Carcaboso, AM; Castillo-Ecija, H; Cuadrado-Vilanova, M; de Alava, E; Lavarino, C; Martinez-Velasco, N; Mora, J; Olaciregui, NG; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Tirado, OM; Vila-Ubach, M | 1 |
| Du, J; Hu, W; Li, J; Tian, Z; Zhao, P; Zhao, Y; Zheng, W | 1 |
| Carlan, SJ; Castaneira, G; Field, Z; Kropf, J; Luc, LT; Oriala, C; Rico, A | 1 |
| Anderson, DM; Erickson, LA; Ernstoff, M; Javed, A; Markovic, SN; Reid, JM; Suman, VJ; Wall, DJ | 1 |
| Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI | 1 |
| Amoroso, L; Bisogno, G; Casanova, M; Castel, V; Chen, N; Chisholm, JC; Doz, F; Fagioli, F; Gerber, NU; Hingorani, P; le Bruchec, Y; Marquez-Vega, C; Melcón, SG; Moreno, L; Ruggiero, A; Simcock, M; Slepetis, R; Vassal, G | 1 |
| Hou, H; Li, Y; Zhang, P; Zhang, Z | 1 |
| Fukui, M; Katsumi, H; Kimura, H; Nakao, Y; Sakane, T; Shimizu, E; Yamamoto, A; Yamashita, S; Yoshioka, A | 1 |
| Bas, O; Ceylan, F; Dizdar, O; Guven, DC; Kilickap, S; Yildirim, HC | 1 |
| Sun, XQ; Xue, S; Zhang, FY; Zhu, SS | 1 |
| Fan, B; Feng, Z; Lu, B; Shi, Y | 1 |
| Elboray, EE; Endo, K; Kajikuri, J; Kito, H; Ohya, S; Suzuki, T | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Funakoshi, T; Hirai, I | 1 |
| Hibino, N; Isobe, Y; Katsumi, H; Naito, C; Tanaka, Y; Yagi, Y; Yamada, S; Yamamoto, A; Yamashita, S | 1 |
| Fujii, K; Ishizuka, S; Saeki, S; Sakata, S; Sasaki, J; Sato, R | 1 |
| Sun, D; Tang, Y; Yao, J; Zhang, M; Zhao, H; Zhu, Z | 1 |
| Alspach, E; Burnette, B; Faget, DV; Flanagan, KC; Fu, Y; Gruosso, T; Johnson, RM; Leahy, K; Luo, X; Mbalaviele, G; Monahan, JB; Murali, B; Park, M; Ren, Q; Ross, MH; Stewart, SA; Su, X; Wang, C; Weilbaecher, KN | 1 |
| Danson, S; Geva, R; Harris, SJ; Joensuu, H; Lopez, J; Peer, A; Pereira, KMC; Perets, R; Souza, F | 1 |
| Chen, XY; Lao, LF; Qiu, ML; Shen, HX; Xiao, WY; Zong, Z | 1 |
| Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
| Akiyama, N; Asada, K; Enomoto, N; Fujii, M; Fujisawa, T; Furuhashi, K; Hozumi, H; Inami, N; Inui, N; Kaida, Y; Karayama, M; Matsuda, H; Matsui, T; Matsuura, S; Nakamura, Y; Suda, T; Suzuki, Y; Toyoshima, M; Uto, T; Yasui, H | 1 |
| Kamata, T; Motono, N; Shimada, K; Uramoto, H | 1 |
| Chen, C; Cui, X; Guo, Z; Lin, D; Wang, S; Xie, C; Zhao, Y; Zhao, Z; Zhou, J | 1 |
| Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y | 1 |
| Caraglia, M; Chiosi, E; Di Maiolo, F; Esposito, A; Naviglio, S; Sapio, L; Sorvillo, L; Spina, A | 1 |
| Alberghini, M; Antonescu, CR; Bertoni, F; Cesari, M; Ferrari, C; Ferrari, S; Maki, RG; Marchesi, E; Mavrogenis, A; Paioli, A; Palmerini, E; Picci, P; Ruggieri, P; Staals, EL | 1 |
| Kim, HJ; Kim, JM; Kim, YJ; Lee, KY; Lee, SG; Park, JE; Yoo, YH | 1 |
| Di, GH; Hu, XC; Jia, Z; Lu, YH; Shao, ZM; Sun, S; Tang, LC; Wang, BY; Zhang, J | 1 |
| Angarita, FA; Meek, E; Rodríguez, JL; Sánchez, JO; Tawil, M; Torregrosa, L | 1 |
| Guo, C; Han, Y; Li, Y; Meng, X; Shen, Z; Wan, L; Yang, Q; Yu, Q; Zhou, Z | 1 |
| Ala-Luhtala, T; Asola, R; Elomaa, L; Heikkinen, M; Huusko, M; Järvenpää, R; Kaleva-Kerola, J; Kellokumpu-Lehtinen, P; Kokko, R; Lehtinen, I; Maiche, A; Möykkynen, K; Tuunanen, T | 1 |
| Chen, MY; Guo, L; Hong, MH; Huang, HQ; Jiang, R; Liu, Q; Mai, HQ; Qian, CN; Qiu, F; Sun, R; Xia, ZJ; Zhang, L; Zou, X | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Mazzocato, C | 1 |
| Cripe, TP; Currier, M; Eaves, D; Wagner, LM; Yin, H | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Choy, E; Cote, G; Duan, Z; Harmon, D; Hornicek, FJ; Mankin, H; Osaka, E; Shen, J; Yang, P; Yang, X; Zhang, Z | 1 |
| Geng, YC; Hu, YX; Li, HQ; Li, QS; Lu, B; Ma, Z; Ouyang, WW; Su, SF | 1 |
| Iida, K; Ishibashi, T; Ishikawa, M; Katagiri, A; Katagiri, H; Miyazaki, K; Nakayama, K; Nakayama, N; Rahman, M; Rahman, MT | 1 |
| Hirokaga, K; Maekawa, Y; Matsuo, Y; Miki, M; Takao, S; Tane, K; Yoshida, S | 1 |
| Choy, E; Cote, G; Duan, Z; Gray, NS; Harmon, D; Hornicek, FJ; Hua, Y; Mankin, H; Shen, J; Ye, S; Zhang, J; Zhang, Y | 1 |
| Elsabahy, M; Fan, J; Gonzalez, AM; Gustafson, TP; Hughes, DM; Johnson, R; Leininger, SE; Lenox, MW; Li, R; Nelson, LD; Pavía-Sanders, A; Pollack, SF; Raymond, JE; Wooley, KL; Zhang, F; Zhang, S; Zou, J | 1 |
| Abe, Y; Hirai, R; Ikeda, E; Kashima, H; Kuroda, M; Kurosaki, T; Miyahara, K; Moriyama, S; Takagi, S; Tsuji, H; Yamano, T; Yoshitomi, S | 1 |
| Wang, B; Xu, M; Xu, SF; Yu, XC | 1 |
| Grothey, A; Phuoc, V | 1 |
| Cai, J; Li, J; Li, Z; Wang, F; Zhao, K; Zou, L | 1 |
| Chen, T; Guo, Y; Huang, C; Huang, Z; Li, G; Li, J | 1 |
| Gui, Q; Li, D; Xia, S; Xu, C; Yu, S; Zhuang, L | 1 |
| Chung, YS; Kang, HC; Lee, T | 1 |
| Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I; Zysk, A | 1 |
| Blassl, C; Chebouti, I; Fehm, T; Kasimir-Bauer, S; Kimmig, R; Neubauer, H; Wimberger, P | 1 |
| Adjei, IM; Labhasetwar, V; Peetla, C; Sharma, B | 1 |
| Fujino, T; Niwa, H; Shitara, M; Suzuki, E; Tanahashi, M; Yoshii, N; Yukiue, H | 1 |
| de Graaf, H; de Groot, SM; Drooger, JC; Erdkamp, FL; Hamberg, P; Heijns, JB; Honkoop, A; Imholz, AL; Jager, A; Kroep, JR; Linn, SC; Portielje, JE; Sleijfer, S; Ten Tije, AJ; van Leeuwen-Stok, AE; van Rossum-Schornagel, QC; van Tinteren, H | 1 |
| Liu, M; Wang, Y; Xiao, X; Xiusheng, H | 1 |
| Fang, P | 1 |
| Chung, HC; Gho, SG; Kim, GM; Kim, SI; Paik, S; Park, HS; Park, S; Sohn, J | 1 |
| Li, F; Lu, Y; Sun, J; Xu, T | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Chen, HQ; He, WZ; Li, ZM; Liao, ML; Lu, S; Wang, JJ; Xiang, JQ; Zhang, J; Zhou, XY; Zhou, Z | 1 |
| Heinrich, G; Loibl, S; Müller, L; Murmann, C; Nekljudova, V; Schwedler, K; von Minckwitz, G; Warm, M | 1 |
| Kikuchi, Y; Kita, T; Kudoh, K; Sato, K; Takano, M | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Dennetta, D; Fedeli, SL; Giordani, P; Graziano, F; Rossi, D; Ugolini, M | 1 |
| Bachelot, T; Colin, C; Fournel, C; Ganne, C; Jacquin, JP; Jaisson-Hot, I; Lenoir, VT; Marechal, F; Mechin-Cretinon, I; Orfeuvre, H; Peaud, PY; Poncet, B; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Aogi, K; Kakishita, T; Nishikawa, K; Ohama, Y; Okita, A; Okita, R; Saeki, T; Taira, N; Takashima, S | 1 |
| Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N | 1 |
| Gong, Y; Hou, M; Huang, M; Lu, Y; Ren, L; Wang, J; Wei, Y; Zhou, L; Zhou, X; Zhu, J | 1 |
| Amato, RJ; Henary, H; Hernandez-McClain, J | 1 |
| Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T; Yoneoka, Y | 1 |
| Erez, R; Miller, K; Satchi-Fainaro, R; Segal, E; Shabat, D | 1 |
| Hauff, P; Hoffmann, J; Käkönen, SM; Klar, U; Stepina, E; Strube, A | 1 |
| Babo, I; Harisi, R; Jeney, A; Kenessey, I; Olah, JN; Paku, S; Pogany, G; Timar, F | 1 |
| Hatake, K; Ishikawa, Y; Kodaira, M; Mishima, Y; Saotome, T; Takahashi, S; Takeuchi, K; Terui, Y; Ueda, K; Yamada, S; Yamamoto, N; Yokoyama, M | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Chen, H; Lin, JR; Xie, B; Xu, ZY; Zhang, WM; Zheng, JH; Zhou, J | 1 |
| Cai, YP; Lin, SJ; Xu, S | 1 |
| Daugaard, G; Gothelf, A; Møller, AK; Pedersen, KD | 1 |
| Brandwein-Gensler, M; Garg, MK; Haigentz, M; Levine, D; Shifteh, K; Smith, RV; Staffenberg, DA; Tlemcani, K | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Bravencová, Z | 1 |
| Azzoli, C; Fang, L; Faoro, L; Hainsworth, JD; Huang, JE; Karlin, D; Russell, K | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Jansen, JA; Kamphuis, GJ; Lopez-Heredia, MA; Öner, FC; Thüne, PC; Walboomers, XF | 1 |
| Benayoun, L; Eldar-Boock, A; Miller, K; Polyak, D; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
| Blijham, GH; Erdkamp, FL; Knibbeler-van Rossum, CT; Lalisang, RI; Loosveld, OJ; Nortier, JW; Rodenburg, CJ; Schouten, HC; Slee, PH; Smals, AE; Tjan-Heijnen, VC; van Bochove, A; Voest, EE; Wals, J; Wils, JA | 1 |
| Clementi, C; Mero, A; Miller, K; Pasut, G; Satchi-Fainaro, R | 1 |
| Güler, N; Koçer, M; Muallaoğlu, S | 1 |
| Chiba, F; Kiyozaki, H; Konishi, F; Saito, M; Shuto, C; Takata, O; Yamada, S; Yoshida, T | 1 |
| Eleftheriadou, E; Galaktidou, G; Gerasimou, G; Gotzamani-Psarrakou, A; Karatzas, N; Kontakiotis, T; Sakkas, L; Sapardanis, I; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Ang, ES; Chim, SM; Feng, HT; Pavlos, NJ; Scaife, RM; Steer, JH; Xu, J; Zheng, MH | 1 |
| Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Pavlidis, N; Pectasides, D; Skarlos, D; Syrigos, K | 1 |
| Ding, Y; Hao, L; Niu, X; Xu, H; Yang, Y; Zhang, Q | 1 |
| Coleman, T; Gangireddy, Vg; Liles, GB; Sostre, GD | 1 |
| Boulaamane, L; Boutayeb, S; Errihani, H | 1 |
| Feng, DP; Gong, WH; Huang, T; Jiang, GJ; Li, XC; Li, XH; Zou, CP | 2 |
| Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A | 1 |
| Gődény, M; Láng, I; Nagy, T; Rubovszky, G; Szász, A | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Anai, S; Harada, T; Ijichi, K; Koga, T; Kubo, N; Nakanishi, Y; Otsubo, K; Takayama, K; Yoneshima, Y | 1 |
| Advani, SH; Bakshi, A; Bapsy, PP; Gangadharan, VP; Goswami, C; Maru, A; Mohapatra, R; Nag, S; Parikh, P; Patil, S; Raghunadharao, D; Raina, V; Ranade, AA; Sambasivaiah, K; Sekhon, JS | 1 |
| Levent, E; Orki, A; Sarıman, N; Saygı, A; Yener, NA | 1 |
| He, CX; Jin, Y; Lin, BC; Shao, L; Ye, X; Zhang, BB; Zhang, YP | 1 |
| Avancès, C; Culine, S; Jacot, W; Sénesse, P | 1 |
| Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S | 1 |
| Bu, CF; Chang, KJ; Chao, TY; Chen, MM; Cheng, AL; Hsu, C; Huang, CS; Lu, YS | 1 |
| Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D | 1 |
| Bar-Eli, M; Doucet, M; Fidler, IJ; Lev, DC; Lewis, V; McGary, EC; Mills, L; Weber, K | 1 |
| De Leonardis, F; Muggeo, P; Rigillo, N; Surico, G | 1 |
| Abebe, L; Bhagwati, N; Jain, D; Marcoullis, G; Talusan, R; Wiernik, PH | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Conte, PF; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Shepherd, DL; Uehara, H | 1 |
| Fan, D; Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Logothetis, C; Mathew, P; Shepherd, DL; Tsan, R; Uehara, H | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Jordan, MA; Kelling, J; Sullivan, K; Wilson, L | 1 |
| Baker, C; Doucet, M; Fidler, IJ; Kim, SJ; Price, JE; Weber, KL | 1 |
| Kampel, LJ | 1 |
| Baba, S; Egawa, S; Fujita, T; Kuruma, H; Shitara, T; Yokoyama, E | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM | 1 |
| Curley, T; Hartley-Asp, B; Kattan, MW; Kelly, WK; Larson, S; Morris, M; Scher, HI; Schwartz, L; Slovin, S; Solit, DB | 1 |
| Doucet, M; Price, JE; Weber, KL | 1 |
| Iwamoto, M; Kobayashi, T; Lee, SW; Nohara, T; Sumiyoshi, K; Tanigawa, N | 1 |
| Braunschweiger, P; De Young, LR; Hamilton, K; Lampidis, TJ; Maschek, G; Priebe, W; Savaraj, N; Tidmarsh, GF | 1 |
| Ando, M; Rai, Y; Sagara, Y; Takahama, T | 1 |
| Chasen, MR; Eek, R; McMichael, G; Mohammed, C; Rapoport, BL; Slabber, C; Vorobiof, DA | 1 |
| Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S | 1 |
| Wu, SX; Xie, CY; Zhang, P | 1 |
| Li, FB; Liao, WM; Liu, ZC; Zhou, JM; Zhu, JJ; Zhu, XF | 1 |
| Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S | 1 |
| Boucher, Y; Garkavtsev, I | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| Hao, CF; Jiang, ZF; Liu, F; Liu, XQ; Shen, G; Song, ST; Sun, JZ; Wang, T; Yan, M; Zhang, SH | 1 |
| Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T | 1 |
| Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
| Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S | 1 |
| Axanova, L; Morré, DJ; Morré, DM | 1 |
| Bekele, BN; Bucana, CD; Fidler, IJ; Hawthorne, VS; Jasser, SA; Kim, SJ; Mandal, M; Myers, JN; Park, YW; Yazici, YD; Yigitbasi, OG; Younes, MN | 1 |
| Byun, JR; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Na, KJ; Song, SY; Yang, DH | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Duan, X; Guan, H; Kleinerman, ES; Zhou, Z | 1 |
| Chou, MC; Chung, JG; Lu, KH; Lue, KH | 1 |
| Nakahara, K; Ogino, T; Osanai, T; Tsuchiya, T | 1 |
| Dewan, P; Lin, DW; Montgomery, RB; Wright, JL | 1 |
| Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
| Abe, N; Fujita, S; Gonda, K; Ishigame, T; Ohki, S; Okada, R; Onogi, H; Saito, M; Sekikawa, K; Suzuki, S; Takenoshita, S | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Yoshino, T; Zenda, S | 1 |
| Arano Bermejo, JI; Cabañas Navarro, L; Capote Armas, LF; González-Palacios Martínez, F; Reguero Callejas, ME; Ruiz Tovar, J | 1 |
| Calzas, J; García, J; Guerra, J; Ruiz-Casado, A; Soria, A | 1 |
| Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S | 1 |
| Banerjee, D; Bertino, JR; Hu, Z; Li, WW; Magro, PG; Mandola, J; Peters, R; Russo, AJ | 1 |
| Amadori, D; Caputo, A; Cognetti, F; Crivellari, D; De Sio, L; Filippelli, G; Gasparini, G; Gion, M; Lambiase, A; Mariani, L; Morabito, A; Papaldo, P; Silingardi, V; Spada, A; Torino, F; Zancan, M | 1 |
| Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
| Fidler, IJ | 1 |
| Katakami, N | 1 |
| Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Block, KI; Ellis, J; Gupta, G; Gyllenhaal, C; Koch, A; Lo, C; Oberbaum, M; Samuels, N; Singer, SR; Tripathy, D | 1 |
| Aoki, H; Harano, M; Higaki, K; Ninomiya, M; Ohno, S; Onoda, T; Sasaki, H; Satoh, D; Shiozaki, Y; Takakura, N; Umeoka, T | 1 |
| Iwama, T; Karasawa, K; Kato, K; Sato, S; Sato, T; Takahashi, T; Tsunozaki, H | 1 |
| Suzuki, M | 1 |
| Chen, CY; Han, F; Lu, LX; Lu, TX; Sun, Y; Zhao, C | 1 |
| Imai, S; Jitsuko, A; Nishikawa, H; Otoshi, M; Takahara, S; Tsubono, M; Wada, Y | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Masuda, N | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Murakawa, Y; Nishino, Y; Ohori, H; Ohtsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T | 1 |
| de Lemos, ML; Ellard, S; Hu, F; Kuik, K; Olivotto, IA; Speers, CH; Taylor, SC; Vu, T | 1 |
| Hiroshima, K; Kasahara, Y; Kuriyama, T; Kurosu, K; Sakao, S; Shinozaki, A; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Terada, J; Yoshida, T | 1 |
| Blum, JL; Clawson, A; Edelman, G; Geister, BV; Kirby, RL; O'Shaughnessy, JA; Pippen, JE; Robert, NJ; Savin, MA | 1 |
| Jin, M; Li, J; Li, Y; Shen, L; Zhang, X | 1 |
| Chen, DF; Feng, QF; Ou, GF; Wang, LH; Wang, M; Xiao, ZF; Yin, WB; Zhang, HX; Zhou, ZM; Zhu, XZ | 1 |
| Burris, HA | 1 |
| Divgi, CR; Goldsmith, SJ; Larson, SM; Macapinlac, HA; Schneider, JA; Scott, AM; Seidman, AD | 1 |
| Barrett, S; Crown, J; Currie, V; Gilewski, T; Gollub, M; Hudis, C; Lepore, J; Seidman, AD; Tiersten, A; Yao, TJ | 1 |
| Bishop, JF; Phillips, KA; Urch, M | 1 |
| Stearns, ME; Wang, M | 2 |
| Aaron, AD | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| DiPaola, RS; Kaufman, A; Mikhail, MM | 1 |
| Benjamin, R; Linke, KA; Moseley, SH; Papadopoulos, NE; Patel, SR; Plager, C; Spirindonidis, CH | 1 |
| Stearns, ME | 1 |
| de Argila, D; Dominguez, JD; Iglesias, L | 1 |
| Kennedy, MJ | 1 |
| Du Bois, A; Hecker, D; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 1 |
| Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G | 1 |
| Gian, VG; Johnson, TJ; Lynch, JW; Marsh, RW; Schuhmacher, C | 1 |
| Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V | 1 |
| Hansson, V; Jahnsen, T; Keryer, G; Landmark, BF; Skålhegg, BS; Taskén, K | 1 |
| Asmar, L; Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, H; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS; Willey, J | 1 |
| Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N | 1 |
| Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M | 1 |
| Bilgrami, SA; Sporn, JR | 1 |
| Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Feenstra, J; Stricker, BH; Vermeer, RJ | 1 |
| Endo, T; Fujimoto, K; Haseyama, Y; Koike, T; Koizumi, K; Nishio, M; Sawada, K; Takashima, H; Yamamoto, S | 1 |
| Chang, YH; Chen, KK; Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Huang, WJ; Lin, AT; Liu, JH; Wang, WS; Yang, MH; Yen, CC | 1 |
| Asrari, F; Attawia, MA; Borden, MD; Herbert, KM; Katti, DS; Laurencin, CT; Uhrich, KE | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Aydiner, A; Karadeniz, A; Sakar, B; Tas, F; Tenekeci, N; Topuz, E | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Carlson, LE; Glück, S; Koski, T | 1 |
| Keogh, P; Kingston, R; Leen, E; Sparkes, J; Stafford-Johnson, D | 1 |
| Becker, AJ; Buttner, R; Rath, W; Rudlowski, C; Wiestler, OD | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Ishikawa, T; Itasaka, H; Kume, K; Matsusaka, T; Ohshiro, T; Ohta, M; Sonoda, K; Tashiro, H; Yamamura, S | 1 |
| Ishihama, H | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP | 1 |
| Ara, KY; Arai, K; Maruo, K; Matsuda, H; Uehara, K | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y | 1 |
| Boletis, J; Chiras, T; Kosmas, C; Kostakis, A; Tsavaris, NB; Vadiaka, M | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Beer, TM; Bubalo, JS | 1 |
6 review(s) available for paclitaxel and Bone Cancer
| Article | Year |
|---|---|
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Epothilones; Female; Fluorouracil; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Tubulin Modulators | 2008 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids | 2002 |
50 trial(s) available for paclitaxel and Bone Cancer
| Article | Year |
|---|---|
Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors | 2020 |
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Topics: Adolescent; Age Factors; Albumins; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Europe; Female; Humans; Infant; Male; Neuroblastoma; Paclitaxel; Progression-Free Survival; Rhabdomyosarcoma; Sarcoma, Ewing; Time Factors; Tissue Distribution; Young Adult | 2020 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Paclitaxel; Radium; Safety | 2019 |
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Nanoparticles; Oxonic Acid; Paclitaxel; Prognosis; Survival Rate; Tegafur | 2019 |
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis | 2013 |
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2016 |
Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Paclitaxel; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2008 |
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Estramustine; Humans; Ketoconazole; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Strontium Radioisotopes; Survival Rate; Treatment Outcome | 2008 |
Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Risk Factors; Treatment Outcome | 2010 |
BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Carboplatin; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Octreotide; Paclitaxel; Peptides, Cyclic; Prognosis; Receptors, Somatostatin; Small Cell Lung Carcinoma; Somatostatin; Survival Rate | 2012 |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones | 2013 |
A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Salvage Therapy; Survival Rate; Young Adult | 2013 |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Synergism; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Pilot Projects; Risk Assessment; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pain; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2003 |
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Dexamethasone; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2003 |
First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Soft Tissue Neoplasms; South Africa; Survival Analysis; Treatment Outcome | 2004 |
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatigue; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2007 |
[Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mucositis; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Remission Induction | 2007 |
[A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Survival Rate | 2007 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Topics: Abdominal Neoplasms; Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2008 |
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Radionuclide Imaging; Recombinant Proteins; Technetium Tc 99m Medronate; Time Factors | 1994 |
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bayes Theorem; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Salvage Therapy | 1995 |
Radiation-recall dermatitis in a patient treated with paclitaxel.
Topics: Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence | 1995 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Chondrosarcoma; Female; Histiocytoma, Benign Fibrous; Humans; Male; Middle Aged; Osteosarcoma; Paclitaxel | 1996 |
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pleural Neoplasms; Treatment Outcome; Ventricular Function, Left | 1997 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Salvage Therapy | 1997 |
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
[Weekly paclitaxel therapy for metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2002 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Paclitaxel; Proportional Hazards Models; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Viscera | 2000 |
170 other study(ies) available for paclitaxel and Bone Cancer
| Article | Year |
|---|---|
SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Topics: Albumins; Animals; Bone Neoplasms; Humans; Mice; Osteonectin; Osteosarcoma; Paclitaxel | 2022 |
Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.
Topics: Animals; Biomimetics; Bone Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Carriers; Humans; Lactic Acid; Mice; Nanoparticles; Osteosarcoma; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution | 2022 |
Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint.
Topics: Apoptosis; bcl-2-Associated X Protein; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Humans; Immunoglobulins; Osteosarcoma; Paclitaxel; RNA, Small Interfering | 2023 |
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Child; Humans; Osteonectin; Paclitaxel; Rhabdomyosarcoma; Sarcoma, Ewing | 2023 |
TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced autophagy and cancer stem cell properties.
Topics: Autophagy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Neoplastic Stem Cells; Paclitaxel | 2023 |
A Case of Thymic Carcinoma with Bone and Cerebral Metastases Treated with Stereotactic Radiosurgery and Chemotherapy.
Topics: Bone Neoplasms; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiosurgery; Thymoma; Thymus Neoplasms; Treatment Outcome | 2019 |
Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Folic Acid; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties | 2020 |
Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Mice; Microscopy, Confocal; Nanoparticles; Osteosarcoma; Paclitaxel; Polyethylene Glycols; Polymers; Thioctic Acid; Tissue Distribution | 2020 |
Dendrimer-based micelles with highly potent targeting to sites of active bone turnover for the treatment of bone metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aspartic Acid; Bone Neoplasms; Cell Line, Tumor; Cholesterol; Dendrimers; Drug Carriers; Drug Compounding; Female; Injections, Intravenous; Male; Melanoma, Experimental; Mice, Inbred C57BL; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats, Wistar; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution | 2020 |
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Sarcoma, Ewing | 2021 |
[Paclitaxel liposome for the treatment of castration-resistant prostate cancer].
Topics: Aged; Bone Neoplasms; China; Humans; Liposomes; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Female; Humans; Male; MicroRNAs; Molecular Targeted Therapy; Osteosarcoma; Paclitaxel; Up-Regulation | 2021 |
Ca
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Humans; Indoles; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Osteosarcoma; Paclitaxel; Potassium Channel Blockers; RNA, Small Interfering; Spheroids, Cellular; Transfection; Tumor Microenvironment; Up-Regulation | 2021 |
Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Genital Neoplasms, Male; Groin; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Paclitaxel; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Treatment Outcome | 2017 |
Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Topics: Animals; Apoptosis; Aspartic Acid; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Female; Flow Cytometry; Fluorescent Dyes; Liposomes; Male; Mice, Inbred C57BL; Osteoclasts; Paclitaxel; Polyethylene Glycols; Time Factors; Tissue Distribution; Tritium | 2018 |
Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pleural Neoplasms; Proteinuria; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2017 |
Paclitaxel and etoposide-loaded Poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Interactions; Drug Liberation; Etoposide; Humans; Microspheres; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2018 |
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Therapy; Female; HEK293 Cells; Humans; Induction Chemotherapy; Intracellular Signaling Peptides and Proteins; Macrophages; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Quality of Life; Stromal Cells; Tumor Microenvironment | 2018 |
Paclitaxel Induce Apoptosis of Giant Cells Tumor of Bone via TP53INP1 Signaling.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Carrier Proteins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Giant Cell Tumor of Bone; Heat-Shock Proteins; Humans; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
Sternal resection and reconstruction for metastasis due to breast cancer: the Marlex sandwich technique and implantation of a pedicled latissimus dorsi musculocutaneous flap.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Bone Substitutes; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Middle Aged; Myocutaneous Flap; Neoadjuvant Therapy; Paclitaxel; Plastic Surgery Procedures; Polypropylenes; Prosthesis Implantation; Ribs; Sternum; Superficial Back Muscles; Surgical Mesh; Tomography, X-Ray Computed | 2019 |
Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Glutamic Acid; Humans; Ligands; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Oligopeptides; Paclitaxel; Tumor Cells, Cultured | 2019 |
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Fluorescein-5-isothiocyanate; Human Umbilical Vein Endothelial Cells; Humans; Mice; Micelles; Neovascularization, Physiologic; Paclitaxel; Polyethylene Glycols; Tibia; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Fluorouracil; Humans; Osteosarcoma; Paclitaxel; Phosphates | 2013 |
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Femoral Neoplasms; Femur; Hemangiosarcoma; Humans; Humerus; Ifosfamide; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pelvic Bones; Radiotherapy; Radiotherapy, Adjuvant; Radius; Retrospective Studies; Skull Neoplasms; Spinal Neoplasms; Treatment Outcome; Ulna; Young Adult | 2014 |
Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Bone Neoplasms; Caspase 3; Cell Death; Cell Line, Tumor; Cytochromes c; Cytoprotection; Humans; Membrane Potential, Mitochondrial; Mitochondria; Osteosarcoma; Paclitaxel; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Review Literature as Topic | 2013 |
ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Line, Tumor; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Paclitaxel; Verapamil; Xenograft Model Antitumor Assays | 2013 |
Weekly paclitaxel--an effective treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2013 |
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
[Cancer, pain and treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Neoplasms; Paclitaxel; Pain; Pain Management; Paraneoplastic Polyneuropathy; Peripheral Nervous System Diseases | 2014 |
Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Bone Neoplasms; Cell Line, Tumor; Child; Drug Evaluation, Preclinical; Female; Humans; Mice; Nanoparticles; Osteonectin; Osteosarcoma; Paclitaxel; Sarcoma, Ewing | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Osteosarcoma; Paclitaxel; Piperidines; Quinolines | 2014 |
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2014 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cerebral Infarction; Chemoradiotherapy; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Ovarian Neoplasms; Paclitaxel | 2014 |
[A case of locally advanced and metastatic breast cancer successfully treated with combination therapy of paclitaxel and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Osteosarcoma; Paclitaxel; Peptide Library; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; src-Family Kinases | 2014 |
Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers.
Topics: Alkynes; Animals; Azides; Bone Neoplasms; Catalysis; Cell Line, Tumor; Copper; Drug Carriers; Drug Liberation; Esters; Half-Life; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Mice; Micelles; Models, Molecular; Molecular Conformation; Nanoparticles; Osteosarcoma; Paclitaxel; Polyethylene Glycols; Polymers; Tissue Distribution | 2015 |
[Two cases of dural metastasis of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemoradiotherapy; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Zoledronic Acid | 2014 |
Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Carriers; Etoposide; Humans; Lactic Acid; Nanoparticles; Osteosarcoma; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Metastatic extramammary Paget's disease responding to weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Paget Disease, Extramammary; Perineum; Skin Neoplasms | 2015 |
X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lignans; Mice; Mice, Nude; Mitochondria; Osteosarcoma; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Paxilitaxel induces apoptosis accompanied by protective autophagy in osteosarcoma cells through hypoxia-inducible factor-1α pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitochondria; Osteosarcoma; Paclitaxel; Signal Transduction | 2015 |
Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Topics: Acid Sensing Ion Channels; Analgesics; Animals; Biomarkers; Bone Neoplasms; Cell Line, Tumor; Collagen Type I; Diphosphonates; Drug Evaluation, Preclinical; Female; Ganglia, Spinal; Hyperalgesia; Imidazoles; Neoplasm Transplantation; Osteoclasts; Paclitaxel; Pain; Peptides; Proto-Oncogene Proteins c-fos; Rats, Wistar; Spinal Cord; Zoledronic Acid | 2015 |
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Ibandronic Acid; Immunocompetence; Male; Neoplasm Metastasis; Osteolysis; Paclitaxel; Rats; Rats, Sprague-Dawley | 2015 |
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Prognosis | 2016 |
Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Humans; Male; Mice, Nude; Nanoparticles; Paclitaxel; Prostatic Neoplasms; Surface Properties; Tibia; Tissue Distribution; X-Ray Microtomography | 2016 |
[A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Lymphangitis; Middle Aged; Paclitaxel; Time Factors | 2016 |
Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Binding Sites; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Osteosarcoma; Paclitaxel; RNA Interference; Transforming Growth Factor beta2 | 2016 |
Internal Mammary Misfortune.
Topics: Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Dose Fractionation, Radiation; Female; Humans; Lymphatic Irradiation; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Radiosurgery; Radiotherapy, Adjuvant; Sternum | 2017 |
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
Topics: ATP Binding Cassette Transporter, Subfamily B; Benzylisoquinolines; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; NF-kappa B; Osteosarcoma; Paclitaxel; Signal Transduction | 2017 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; bcl-X Protein; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Incidence; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2008 |
Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2008 |
Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Skin Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2008 |
Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution; Toremifene; Treatment Outcome | 2009 |
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Paclitaxel; Retrospective Studies; Soft Tissue Neoplasms; tau Proteins; Treatment Outcome; Young Adult | 2009 |
Advanced gastric cancer patient with peritonitis carcinomatosa successfully treated with a combination therapy of paclitaxel and TS-1, but relapsed with multiple bone metastasis and died from rapidly progressive meningitis carcinomatosa--advanced gastric
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Combinations; Fatal Outcome; Humans; Male; Meningitis; Middle Aged; Oxonic Acid; Paclitaxel; Peritonitis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Bridged-Ring Compounds; Cathepsin B; Cells, Cultured; Humans; Paclitaxel; Polymers; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Topics: Acid Phosphatase; Animals; Antineoplastic Agents, Phytogenic; Benzothiazoles; Bone and Bones; Bone Neoplasms; Bone Resorption; Cachexia; Cell Line, Tumor; Dose-Response Relationship, Drug; Epothilones; Female; Humans; Isoenzymes; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Osteoclasts; Osteolysis; Paclitaxel; Tartrate-Resistant Acid Phosphatase; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Differential inhibition of single and cluster type tumor cell migration.
Topics: Adolescent; Bone Neoplasms; Cell Culture Techniques; Cell Movement; Cell Proliferation; Chromones; Deoxyuridine; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibrosarcoma; Flavonoids; Humans; Imidazoles; Male; Morpholines; Okadaic Acid; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Signal Transduction; Tumor Cells, Cultured | 2009 |
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma; Cohort Studies; Female; Health Status; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Task Performance and Analysis | 2010 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Young Adult | 2009 |
[Comparison of outcomes of Taxol + Cisplatin and Taxol + Nedaplatin chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Young Adult | 2010 |
Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatal Outcome; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Paclitaxel; Scalp; Sweat Gland Neoplasms; Young Adult | 2010 |
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
[A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction | 2010 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
An injectable calcium phosphate cement for the local delivery of paclitaxel to bone.
Topics: Biological Availability; Bone Cements; Bone Neoplasms; Breast Neoplasms; Calcium Phosphates; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Delivery Systems; Durapatite; Female; Humans; Microscopy, Electron, Scanning; Osteosarcoma; Paclitaxel; Photoelectron Spectroscopy; Porosity; Serum Albumin | 2011 |
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukocyte Count; Mice; Mice, Inbred BALB C; Paclitaxel | 2011 |
Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dendrimers; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Paclitaxel; Polyethylene Glycols; Rats | 2011 |
Acute transient encephalopathy after weekly paclitaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Diseases; Breast Neoplasms; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2012 |
Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Bone Resorption; Cell Line; Cytoskeleton; Extracellular Signal-Regulated MAP Kinases; Giant Cell Tumor of Bone; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred C57BL; Mitosis; NF-kappa B; Osteoclasts; Osteolysis; Paclitaxel; RANK Ligand | 2012 |
The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Osteonectin; Osteosarcoma; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Experimental; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Medullary; Fatal Outcome; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Sickle Cell Trait; Treatment Outcome | 2012 |
Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Meta-Analysis as Topic; Middle Aged; Morocco; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2012 |
Induction of apoptosis by a combination of paclitaxel and carboplatin in the presence of hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Carboplatin; Combined Modality Therapy; fas Receptor; Fever; Humans; Immunoenzyme Techniques; Osteosarcoma; Paclitaxel; Tumor Cells, Cultured | 2012 |
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diphosphonates; Humans; Hyperthermia, Induced; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Etoposide; fas Receptor; Humans; Osteosarcoma; Paclitaxel; Temperature | 2012 |
Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Staging; Neoplasms, Muscle Tissue; Paclitaxel; Positron-Emission Tomography; Radiography; Thoracic Vertebrae; Treatment Outcome | 2012 |
Lung cancer and pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Treatment Outcome | 2013 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Outcome Assessment, Health Care; Paclitaxel; Palliative Care; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Young Adult | 2013 |
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Humans; Male; Paclitaxel; Platelet Count; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids | 2002 |
Radiation recall dermatitis from docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids | 2002 |
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Mice; Neoplasm Transplantation; Osteosarcoma; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tibia; Time Factors; Tumor Cells, Cultured | 2002 |
New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma-preliminary report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Fatal Outcome; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Paclitaxel; Retroperitoneal Neoplasms; Salvage Therapy; Taxoids | 2003 |
Microangiopathic hemolysis refractory to plasmapheresis responding to docetaxel and cisplatin: a case report.
Topics: Adenocarcinoma; Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Hemolysis; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Plasmapheresis; Taxoids | 2002 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone and Bones; Bone Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; ErbB Receptors; Fibroblast Growth Factor 2; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Neoplasms, Experimental; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tumor Cells, Cultured | 2003 |
Suppression of centromere dynamics by Taxol in living osteosarcoma cells.
Topics: Antineoplastic Agents, Phytogenic; Autoantigens; Bone Neoplasms; Cell Division; Centromere; Centromere Protein B; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Luminescent Proteins; Microtubules; Mitosis; Osteosarcoma; Paclitaxel; Recombinant Fusion Proteins; Spindle Apparatus; Tumor Cells, Cultured | 2003 |
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Division; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Recombinant Proteins; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bone Neoplasms; Disseminated Intravascular Coagulation; Fatal Outcome; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2003 |
Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Renal Cell; ErbB Receptors; Kidney Neoplasms; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Tumor Cells, Cultured | 2003 |
[Examination of therapy using trastuzumab in patients with metastatic breast carcinoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Remission Induction; Trastuzumab | 2003 |
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Doxorubicin; Drug Synergism; Humans; Lung Neoplasms; Mice; Mice, Nude; Osteosarcoma; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
[Effective weekly paclitaxel therapy for massive metastatic breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Radical; Paclitaxel; Pamidronate; Quality of Life | 2004 |
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays | 2004 |
[Efficacy of combined paclitaxel and oxaliplatin therapy in patients with pretreated advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Treatment Outcome | 2004 |
The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; DNA Repair; DNA-Binding Proteins; Genes, p53; Genes, Tumor Suppressor; Growth Inhibitors; Humans; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Nuclear Proteins; Osteosarcoma; Paclitaxel; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 2005 |
An intact ING1-P53 pathway can potentiate the cytotoxic effects of taxol.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Genes, p53; Genes, Tumor Suppressor; Humans; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; NF-kappa B; Nuclear Proteins; Osteosarcoma; Paclitaxel; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
[Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction | 2005 |
[A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Disseminated Intravascular Coagulation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Methotrexate; Middle Aged; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Uracil | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid | 2005 |
Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bone Neoplasms; Capsaicin; Catechin; Cell Survival; Cisplatin; Humans; Isoflavones; Male; Osteoblasts; Paclitaxel; Plant Extracts; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Nude; Osteoclasts; Osteoprotegerin; Paclitaxel; Radiography; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Zoledronic Acid | 2005 |
Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS).
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Osteosarcoma; Paclitaxel | 2005 |
Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Endometrial Neoplasms; Epirubicin; Female; Humans; Paclitaxel; Pamidronate | 2006 |
Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Bone Neoplasms; Hematuria; Humans; Hydronephrosis; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Renal Dialysis; Renal Insufficiency; Tumor Lysis Syndrome | 2005 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
[A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Gastrectomy; Humans; Lung Neoplasms; Lymph Node Excision; Paclitaxel; Quality of Life; Stomach Neoplasms | 2006 |
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2006 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Fatal Outcome; Female; Femoral Neoplasms; Humans; Hysterectomy; Ifosfamide; Ilium; Middle Aged; Mixed Tumor, Mullerian; Neoplasms, Second Primary; Ovariectomy; Paclitaxel; Palliative Care; Pelvic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Sarcoma, Ewing; Spinal Neoplasms; Uterine Neoplasms | 2006 |
Life-threatening adverse drug reaction to paclitaxel. Postmarketing surveillance.
Topics: Adenocarcinoma; Adrenergic Agents; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; Atropine; Bone Neoplasms; Bradycardia; Bundle-Branch Block; Cardiopulmonary Resuscitation; Combined Modality Therapy; Dexamethasone; Dyspnea; Epinephrine; Female; Heart Arrest; Humans; Hypotension; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Product Surveillance, Postmarketing; Respiration, Artificial | 2006 |
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured | 2006 |
E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.
Topics: Bone Neoplasms; CDC2 Protein Kinase; Cell Growth Processes; Cell Line, Tumor; Cyclin B; Cyclin B1; E2F1 Transcription Factor; Humans; Osteosarcoma; Paclitaxel; RNA Interference; RNA, Messenger; Transfection; Vinblastine | 2006 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Integrative tumor board: metastatic breast cancer.
Topics: Acupuncture Therapy; Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Complementary Therapies; Drugs, Chinese Herbal; Female; Gallbladder Neoplasms; Homeopathy; Humans; Middle Aged; Paclitaxel | 2006 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Disseminated Intravascular Coagulation; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2006 |
[Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Catheter Ablation; Docetaxel; Fatal Outcome; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Taxoids; Trastuzumab | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate | 2007 |
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; British Columbia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[A case of angiosarcoma of pelvis with pulmonary metastases which responded to paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Bones; Salvage Therapy | 2007 |
[Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Particle Accelerators; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2007 |
Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol.
Topics: Animals; Antibody Specificity; Blotting, Western; Bone Neoplasms; Cell Division; Clone Cells; Enzyme-Linked Immunosorbent Assay; Gelatinases; Glycoproteins; Humans; Immunoassay; Immunoblotting; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1994 |
The management of cancer metastatic to bone.
Topics: Acetabulum; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Femur; Fractures, Spontaneous; Hip Prosthesis; Humans; Middle Aged; Paclitaxel; Pain; Tomography, X-Ray Computed | 1994 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Tamoxifen | 1996 |
Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice.
Topics: Animals; Bone Neoplasms; Cell Survival; Humans; Idoxuridine; Keratins; Male; Mice; Mice, SCID; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured | 1995 |
Taxol-induced acral erythema.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Paclitaxel | 1996 |
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Lumbar Vertebrae; Male; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Prostatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 1996 |
A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Sarcoma; Soft Tissue Neoplasms | 1996 |
Differential localization of protein kinase A type II isozymes in the Golgi-centrosomal area.
Topics: Antibodies, Monoclonal; Bone Neoplasms; Cell Line, Transformed; Cells, Cultured; Centrosome; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Female; Fibroblasts; Golgi Apparatus; Granulosa Cells; Humans; Isoenzymes; Keratinocytes; Lymphocytes; Macrophages; Microscopy, Confocal; Microscopy, Fluorescence; Microtubules; Neoplasm Proteins; Nocodazole; Osteosarcoma; Paclitaxel; Second Messenger Systems; Subcellular Fractions; Trophoblasts; Tumor Cells, Cultured | 1999 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
Taxane-induced glaucoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids | 1999 |
Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Genes, erbB-2; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Trastuzumab | 1999 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Mesenteric venous thrombosis attributed to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Osteolysis; Paclitaxel; Sternum; Taxoids; Venous Thrombosis | 2000 |
[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Renal Insufficiency; Survival Analysis; Urinary Bladder Neoplasms | 2000 |
Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Bone Neoplasms; Cell Cycle; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Delivery Systems; Flow Cytometry; Hexanes; Humans; Microscopy, Electron, Scanning; Microspheres; Paclitaxel; Particle Size; Polymers; Radiation-Sensitizing Agents; Sarcoma, Ewing; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Hypertrophic osteoarthropathy associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paclitaxel; Taxoids | 2001 |
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Topics: Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2001 |
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arthralgia; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Depression; Female; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Middle Aged; Mitoxantrone; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Transplantation, Autologous | 2001 |
Bone metastasis as the presenting complaint in ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Fatal Outcome; Female; Humans; Ovarian Neoplasms; Paclitaxel; Shoulder Pain | 2001 |
Trastuzumab and breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Diphosphonates; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pamidronate; Receptor, ErbB-2; Trastuzumab | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
[Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil | 2001 |
High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Topics: Adult; Anthracyclines; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Breast Neoplasms; Cell Separation; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Characterization of isotype-specific regions of five classes of canine beta-tubulin and their expression in several tissues and cell culture.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Dog Diseases; Dogs; Female; Gene Expression Regulation, Neoplastic; Male; Mammary Neoplasms, Animal; Mice; Mice, SCID; Molecular Sequence Data; Osteosarcoma; Paclitaxel; Polymerase Chain Reaction; Protein Isoforms; Sequence Homology, Amino Acid; Tubulin; Tumor Cells, Cultured | 2001 |
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome | 2000 |
Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chromosome Aberrations; Chromosomes, Human, Pair 12; Diagnosis, Differential; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Paclitaxel; Pelvic Neoplasms; Seminoma | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |